Tome Biosciences, Funded with $213M, Seeks Buyer by November 1 Amid Layoffs

Tome Biosciences, a preclinical gene-editing startup that launched with $213 million in funding, is facing significant challenges. The company, a leader in the gene insertion field, is reportedly winding down operations and seeking a buyer by November 1. It has been unable to secure new funding or find a partner to continue its laboratory work. As a result, Tome Biosciences has filed a notice to lay off 131 employees, nearly its entire workforce, in the first two weeks of November. The company's CEO, Rahul Kakkar, has acknowledged the dire situation in an interview.